Sensei Biotherapeutics Azioni (NASDAQ: SNSE)

Ultime notizie per Sensei Biotherapeutics (NASDAQ:SNSE) Azioni

Sensei Biotherapeutics

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

The S&amp;P 500 index could still be hovering in the bubble territory as the cyclical adjusted price-to-earnings ratio, or the S&amp;P 500 Shiller CAPE ratio, remains above the level of 30 for 18 consecutive months, underscoring a rare historical trend.
What Happened: Unlike the trailing P/E, the Shiller P/E is a valuation methodology that uses a 10-year inflation-adjusted average EPS, smoothing out the impact of short-term shocks and recessions on valuation.
According to an X post by Katusa Research, the market is &#8220;approaching bubble territory,&#8221; as this metric was nearly twice its historical average of 17.58.
&#8220;By this measure (recent correction included), stocks are still historically expensive,&#8221; the post stated.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Shiller CAPE: Approaching Bubble Territory The Cyclically Adjusted Price-to-Earnings ratio (made by Robert Shiller) smooths out short-term earnings fluctuations By using 10 years of inflation-adjusted earnings. The current CAPE ratio stands at 34.97, more than double its… <a href="https://t.co/qgmkFxkP09">pic.twitter.com/qgmkFxkP09</a>
&mdash; Katusa Research (@KatusaResearch) <a href="https://twitter.com/KatusaResearch/status/1912948966070894869?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to the data by YCharts, the CAPE ratio was above the level of 30 for the 17th consecutive month in March and hovered at approximately 33.12 for April as of Thursday&#8217;s close.
According to a report by Motley Fool, over the last 154 years, the CAPE ratio has surpassed the level of 30 for two consecutive months, <a href="https://www.fool.com/investing/2024/12/15/stock-market-threshold-6-times-1871-history-says/?utm_source=nasdaq&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=f28929f2-4dcd-438a-8500-696d9ca0cb67">only six times</a>. 
Moreover, the S&amp;P 500 index formed a <a href="https://www.benzinga.com/25/04/44805223/the-sp-500-closes-with-first-death-cross-since-2022-heres-what-it-means-for-the-markets">death cross</a> for the first time since March 2022 last week. According to i3 Invest CEO, Guilherme Tavares, the death cross, combined with an elevated CAPE ratio, has been historically observed only three times before April 2025. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That&#39;s it folks. The S&amp;P 500 has just triggered a death cross for the first time following a CAPE ratio that exceeded two standard deviations above its long-term exponential trend. The other 3 times this happened: &#8211; Nov/1929 &#8211; Oct/2000 &#8211; Mar/2022 Place your bets. <a href="https://t.co/hoUdiAcOIx">pic.twitter.com/hoUdiAcOIx</a>
&mdash; Guilherme Tavares (@i3_invest) <a href="https://twitter.com/i3_invest/status/1912959249065611663?ref_src=twsrc%5Etfw">April 17, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-chinas-interests">Xi Jinping&#8217;s China Pledges Retaliation Against Countries Isolating Beijing By Giving Into Trump Administration&#8217;s &#8216;Unilateral Bullying,&#8217; Says It Will &#8216;Never Accept It&#8217;</a>
Why It Matters: The selloff is triggered by President Donald Trump&#8216;s tariffs, which have created uncertainty among investors and businesses worldwide.
While <a href="https://www.benzinga.com/25/04/44891949/chinese-commerce-ministry-pledges-retaliation-against-countries-isolating-beijing-with-us-at-the-expense-of-chinas-interests">China has been central</a> in the tariff imposition and retaliation, the administration halted the tariffs on other countries for 90 days on April 9. However, the sector-specific tariffs continue to keep the stocks on edge.
As of Thursday&#8217;s close, the S&amp;P 500 index was down 14.1% from its all-time high of 6,147.43 points. The Dow Jones Industrial Average was 13.15% below its 52-week high, whereas the Nasdaq 100 index was 17.84% lower than its previous record.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.99% to $521.20, while the QQQ declined 1.08% to $439.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44892375/dean-of-valuation-aswath-damodaran-warns-buying-the-dip-akin-to-catching-a-falling-">Dean Of Valuation Aswath Damodaran Warns Buying The Dip Akin To Catching A Falling Knife, Says It Takes A &#8216;Stronger Stomach&#8217; Than Most Have</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

News

Markets

Analyst Ratings

General

S&P 500 'Approaching Bubble Territory:' US Stocks Remain Historically Overvalued Despite Recent Correction, Says Market Researcher

Jefferies analyst John Aiken downgrades Canadian Imperial Bank (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CM#TSX">CM</a>) from Buy to Hold and lowers the price target from C$100 to C$89.

Downgrades

Price Target

TSX:CM

Jefferies Downgrades Canadian Imperial Bank to Hold, Lowers Price Target to C$89

TCBI

Axxess And Texas Capital Unveil Integration To Speed Up Payer Remittance For Care At Home Providers

In a historic first, humanoid robots ran alongside human participants in a half-marathon in Beijing, showcasing both the advancements and ongoing challenges within the robotics industry.
What Happened: The 2025 Beijing E-Town Humanoid Robot Half Marathon, held on Saturday, featured over 12,000 human participants and 21 humanoid robots, according <a href="https://www.businessinsider.com/photos-humanoid-robots-half-marathon-beijing-china-2025-4">to</a> Business Insider. 
The robots, each with a unique design, ran in a separate lane from the human runners.
The robots had approximately three and a half hours to finish the course, with awards in three categories: race completion, best endurance, and most popular robot.
Despite rigorous preparation, not all robots were able to finish the race. Some tripped and fell, while others veered off course.
See Also:&nbsp;<a href="https://benzinga.com/markets/25/04/44892201/2025-largely-doesnt-matter-for-tesla-says-gene-munster-elon-musk-company-poised-for-a-major-rebound-in-20" target="_blank" rel="noreferrer noopener">2025 &#8216;Largely Doesn&#8217;t Matter&#8217; For Tesla, Says Gene Munster: Elon Musk Company Poised &#8216;For A Major Rebound In 2026 And Beyond&#8217;</a>
Nevertheless, Tien Kung Ultra, a robot designed by the&nbsp;Beijing Humanoid Robot Innovation Center,&nbsp;made history by becoming&nbsp;the first humanoid robot to&nbsp;complete the race&nbsp;in 2 hours and 40&nbsp;minutes.
Li Quan, deputy head of&nbsp;the Beijing Economic-Technological Development Area,&nbsp;stated that the event could &#8220;spark discussions and deepen the&nbsp;public&#8217;s understanding of robot capabilities,&#8221; thereby propelling the industry&#8217;s growth.
Why It Matters: This <a href="https://www.benzinga.com/content/44716190/not-just-a-sporting-event-but-also-a-technological-test-insights-into-the-worlds-first-human-robot-c">event is not just a sporting spectacle</a> but also a technological test. The race comes at a time when tech giants like&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and&nbsp;Meta Platforms Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) are reportedly vying to <a href="https://www.benzinga.com/tech/25/02/43759759/apple-and-meta-in-race-to-develop-ai-powered-humanoid-robots">develop AI-powered humanoid robots.</a>
Moreover, Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) CEO Marc Benioff has expressed his belief in <a href="https://www.benzinga.com/news/25/03/44517394/the-future-of-cheap-scalable-digital-labor-marc-benioff-shares-video-of-a-chinese-robot-doing-kung-fu-that-costs-less-than-a-macbook">AI-powered agents and humanoid robots</a> as the future of digital labor. This marathon serves as a real-world demonstration of the potential and limitations of these technologies. Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Read Next:
<ul>
<li><a href="https://benzinga.com/news/25/04/44885628/mark-cuban-says-health-insurance-shouldnt-exist-you-dont-have-to-grab-every-nickel-when-its-the-health-of-th" target="_blank" rel="noreferrer noopener">Mark Cuban Says Health Insurance Shouldn&#8217;t Exist — &#8216;You Don&#8217;t Have to Grab Every Nickel When It&#8217;s the Health of the Entire Country at Stake&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

AAPL

Humanoid Robots Make History In Beijing Half-Marathon, Completes Race In Under 3 Hours

Axxess, the leading global technology platform for healthcare at home, and Texas Capital, a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers, announced a product integration that will enable faster payment reconciliation for home health and hospice providers. The integration between Texas Capital's RevNow product and Axxess RCM optimizes the back-office payer reconciliation workflow using sophisticated automation that matches payments and remittances, eliminating the need for manually tracking payments.

Axxess and Texas Capital Launch Automation to Simplify Payment Tracking for Healthcare Providers

"Being recognized as a Transparency Project by the White House underscores the immense strategic value of the Stibnite Gold Project," said Jon Cherry, President and CEO of Perpetua Resources. "We are honored by this selection, which validates the urgency and importance of our Project for America's economic and national security. We stand ready to restore the site and bolster American mineral independence."

PPTA

Perpetua Resources' Stibnite Gold Project Named White House Priority For Strengthening U.S. Mineral Independence

The ONE by ONE Recycling program has collected over 101 million used contact lenses, blister packs and top foils since the program's launch in November 2016. The Biotrue Eye Care Recycling program, which launched in April 2021, has collected over 1.3 million eye drop single dose units, lens cases and lens solution caps, as well as all Biotrue-branded eye drop bottles2. Bausch + Lomb has a similar contact lens recycling program in Canada called Every Contact Counts.

BLCO

Bausch + Lomb's ONE By ONE And Biotrue Eye Care Recycling Programs Collect Over 100M Units Of Used Materials

Janney Montgomery Scott analyst Timothy Coffey upgrades Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) from Neutral to Buy.

Upgrades

BANR

Janney Montgomery Scott Upgrades Banner to Buy

<ul>
<li>AMG to acquire a minority equity interest in Verition, a global multi-strategy investment firm with $12.6 billion in AUM</li>
<li>Verition's management will retain a substantial majority of the firm's equity and continue to lead Verition as an independent firm, in line with AMG's partnership approach</li>
<li>Partnership further diversifies AMG's business and increases its exposure to alternative strategies</li>
</ul>

AMG Acquires Minority Stake In Verition Fund Management, Expanding Alternative Investment Strategies

Creating symmetrical, same-size gold nanospheres in microgravity that could accelerate speed and accuracy of blood tests for cancer, other diseases

Redwire Expands Drug Development In Microgravity With PIL-BOX And New Cancer-Detection Experiment On ISS

Health Care

CTSO

CytoSorbents Received $1.7M In Cash Proceeds From The Sale Of Its 2023 And Amended 2022 Net Operating Loss And R&D Tax Credits From The Technology Business Tax Certificate Transfer Program, Sponsored By The New Jersey Economic Development Authority

MLEC

Moolec Science Sa Announced That It Has Entered Into A Business Combination Agreement With Bioceres Group Limited and Other Related Entities In An All-stock Transaction

Earnings

Earnings Beats

HBT Finl Q1 2025 Adj. EPS $0.61 Beats $0.57 Estimate, Sales $58.014M Beat $57.380M Estimate

Biotech

ARVN

Arvinas Announced That New Preclinical Combination Data For ARV-393 Will Be Presented At The American Association For Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, April 21, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>, HKEX: 6855))), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for hematological malignancies, today announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), the company's investigational novel oral Bcl-2 selective inhibitor, received its first recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. Olverembatinib, the company's novel next-generation tyrosine kinase inhibitor (TKI), received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescent, and retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies.
 &nbsp;

AAPG

Ascentage Pharma's Proprietary Novel Drugs Lisaftoclax And Olverembatinib Included In 2025 Chinese Society Of Clinical Oncology Guidelines

WIIM

IVVD

Invivyd shares are trading higher after the company signed a $30 million term loan facility with Silicon Valley Bank.

UTHR

United Therapeutics Announces Series Of Presentations And Sponsored Events At ATS 2025, Highlighting Pulmonary Hypertension And Fibrosis Studies

Financing

Invivyd Signs $30M Term Loan Facility With Silicon Valley Bank

Canaccord Genuity analyst Maria Ripps maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Buy and raises the price target from $1150 to $1200.

NFLX

Canaccord Genuity Maintains Buy on Netflix, Raises Price Target to $1200

Guaranty Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNTY#NYSE">GNTY</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.71 by 5.63 percent. This is a 29.31 percent increase over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $31.76 million which beat the analyst consensus estimate of $31.10 million by 2.13 percent. This is a 10.10 percent increase over sales of $28.84 million the same period last year.

GNTY

Guaranty Bancshares Q1 2025 GAAP EPS $0.75 Beats $0.71 Estimate, Sales $31.76M Beat $31.10M Estimate

Press Releases

Sensei Biotherapeutics to Present at Upcoming Conferences

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Comments

Sensei Biotherapeutics

Notizie

Ultime notizie per Sensei Biotherapeutics (NASDAQ:SNSE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO